RemeGen Co (HKSE:09995) Cash-to-Debt : 0.56 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. RemeGen Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.56.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, RemeGen Co couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for RemeGen Co's Cash-to-Debt or its related term are showing as below:

HKSE:09995' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.53 Med: 6.83 Max: 17.09
Current: 0.56

During the past 6 years, RemeGen Co's highest Cash to Debt Ratio was 17.09. The lowest was 0.53. And the median was 6.83.

HKSE:09995's Cash-to-Debt is ranked worse than
83.71% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs HKSE:09995: 0.56

RemeGen Co Cash-to-Debt Historical Data

The historical data trend for RemeGen Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

RemeGen Co Cash-to-Debt Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.53

14.00

17.09

12.54

0.56

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial									12.54	1.97	N/A	0.56	N/A

Competitive Comparison of RemeGen Co's Cash-to-Debt

For the Biotechnology subindustry, RemeGen Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Cash-to-Debt falls into.

RemeGen Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

RemeGen Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	775.569	/	(377.047	+	1001.095)
	=	0.56

RemeGen Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	775.569	/	(377.047	+	1001.095)
	=	0.56

RemeGen Co (HKSE:09995) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

RemeGen Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines